Novel alginate and cellulose derivative based composition of the liquid anti-reflux formulation
AssigneesNutrition & Biosciences USA 1, LLC, Danisco India Pvt. Ltd.
InventorsAtul Ashok Kumar Lohade, Vinay Muley, Rathmaker Palarapu, Matthias Knarr
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical raft-forming suspensions suitable for oral treating gastroesophageal reflux diseases, methods for its preparation, as well as the use in the treatment of a gastroesophageal reflux disease.
Claims23
A pharmaceutical raft-forming suspension suitable for the treatment by oral administration of gastroesophageal reflux diseases comprising:
- a) an alginate in the amount of 2% (w/w) to 5% (w/w);
- b) a cellulose derivative polymer selected from the group consisting of hydroxypropyl methylcellulose (HPMC), carboxymethyl cellulose (CMC), and methylcellulose (MC), hydroxypropyl cellulose (HPC);
- and mixtures thereof;
- c) a carbonate;
- d) a multivalent alginate cross-linking ion in an amount of about 1.1% (w/w) to 2.2% (w/w);
- e) at least one viscosifier selected from i) a hydrocolloid, and ii) a pharmaceutically acceptable poly-acrylic acid;
- and
- f) water or other pharmaceutical vehicle.
-13. (canceled)
A method for the preparation of a raft-forming suspension comprising the steps of mixing the components of:
- a) an alginate in the amount of 2% (w/w) to 5% (w/w);
- b) a cellulose derivative polymer selected from the group consisting of hydroxypropyl methylcellulose (HPMC), carboxymethyl cellulose (CMC), and methylcellulose (MC), hydroxypropyl cellulose (HPC);
- and mixtures thereof;
- c) a carbonate;
- d) a multivalent alginate cross-linking ion in an amount of about 1.1% (w/w) to 2.2% (w/w);
- e) at least one viscosifier selected from i) a hydrocolloid, and ii) a pharmaceutically acceptable poly-acrylic acid;
- and
- f) water or other pharmaceutical vehicle.
(canceled)
A method for the treatment of a gastroesophageal reflux disease comprising the administering of an effective amount to a subject in need thereof of a raft-forming suspension comprising:
- a) an alginate in the amount of 2% (w/w) to 5% (w/w);
- b) a cellulose derivative polymer selected from the group consisting of hydroxypropyl methylcellulose (HPMC), carboxymethyl cellulose (CMC), and methylcellulose (MC), hydroxypropyl cellulose (HPC);
- and mixtures thereof;
- c) a carbonate;
- d) a multivalent alginate cross-linking ion in an amount of about 1.1% (w/w) to 2.2% (w/w);
- e) at least one viscosifier selected from i) a hydrocolloid, and ii) a pharmaceutically acceptable poly-acrylic acid;
- and
- f) water or other pharmaceutical vehicle.
(canceled)
Dependencies are inferred from the claim text.